Shopping Cart 0
Cart Subtotal
USD 0

Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women's health; and vitamins, minerals and supplements. The R&D efforts of Sanofi include working on combination drugs to increase the effectiveness of treatments and advancing the formulation of new biologics to produce medicines with precision. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Sanofi, Medical Equipment Deals By Type, 2012 to YTD 2018 9

Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Sanofi, Medical Equipment, Deals By Market, 2012 to YTD 2018 11

Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 12

Sanofi, Medical Equipment, Deal Details 15

Asset Purchase 15

Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 15

Sanofi Plans to Acquire Medical Device Assets 16

Venture Financing 17

True North Therapeutics Raises USD45 Million in Series D Financing 17

Portal Instruments Raises USD25 Million in Series B Financing 18

Portal Instruments Raises USD11 Million in Series A Venture Financing 19

Private Equity 20

Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 20

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 22

Partnerships 23

Ablynx Exercises Option for Licensing Agreement with Vectura 23

Sensile Medical, Sanofi and Verily Enter into Co-Development Agreement 24

Adaptive Biotechnologies Enters into Agreement with Sanofi 25

Berg Enters into Research Agreement with Sanofi 26

Bioverativ and Invicro Enter into Agreement 27

Sanofi and Voluntis Enter into Agreement 28

R-Health Enters into Agreement with Bioverativ 29

Sanofi and Verily Life Sciences Form Joint Venture 30

Global Genomics Enters into Research Agreement with Sanofi 31

Google Life Sciences Enters into Agreement with Sanofi 32

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33

Sanofi Enters into Co-Development Agreement with Medtronic 34

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 35

HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 36

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 37

Merger 38

Sanofi Japan and Genzyme Japan Merge 38

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 39

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 40

Equity Offering 41

JHL Biotech Raises USD80 Million in Private Placement of Shares 41

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 42

Ablynx Raises USD57 Million in Private Placement of Shares 43

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 44

Debt Offering 45

Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 45

Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 46

Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 47

Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 48

Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 49

Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 50

Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 51

Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 52

Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 53

Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 54

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 55

Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 56

Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 57

Sanofi Prices Public Offering Of Bonds Due 2023 For USD 1.35 Billion 58

Sanofi Prices Public Offering Of Bonds Due 2020 For USD 1.3 Billion 59

Sanofi Completes Public Offering Of Notes Due 2018 For USD 1.5 Billion 60

Sanofi Completes Public Offering Of Notes Due 2017 For USD 960 Million 62

Acquisition 63

Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 63

Bioverativ Therapeutics Acquires True North Therapeutics 65

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 66

Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For USD 123 Million 67

L'Oreal Plans To Sell Its Stake In Sanofi 68

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 69

Sanofi Completes Acquisition Of Pluromed 71

Sanofi-Key Competitors 72

Sanofi-Key Employees 73

Sanofi-Locations And Subsidiaries 75

Head Office 75

Other Locations & Subsidiaries 75

Joint Venture 89

Recent Developments 90

Strategy And Business Planning 90

Sep 13, 2018: Sanofi to refocus two global business units 90

Financial Announcements 91

Mar 28, 2018: Sanofi: Pre-quarterly R esults C ommunication 91

Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 93

Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 100

Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 106

Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 108

Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 114

Corporate Communications 122

Jul 26, 2018: Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st 122

Jun 19, 2018: Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer 123

May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel 124

Apr 24, 2018: Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 125

Mar 06, 2018: Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director 126

Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee 127

Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 128

Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 129

Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 131

Mar 02, 2017: Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 132

Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 133

Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 134

Legal and Regulatory 135

Dec 31, 2017: Sanofi reaches civil settlement with US SEC 135

Other Significant Developments 136

Jun 13, 2018: DTxDM-the Home of Validated Digital Healthcare, Announces Its Founding Partners at the Launch of the New Hub for Everyone Working in Digital Therapeutics and Digital Medicine 136

May 28, 2018: Beactica Signs Three-Year Extension Agreement With Sanofi 137

Apr 27, 2018: Sanofi: First-quarter 2018 Business EPS up 1.4% at CER 138

Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 145

Nov 16, 2017: Blue Cross and Blue Shield Companies Partner with Onduo on Three State Pilot Programs to Address Diabetes 147

Sep 25, 2017: Innovation Health Announces Pilot Program with Sanofi to Improve Care Delivery for People Living with Type 2 Diabetes 148

Appendix 149

Methodology 149

About GlobalData 149

Contact Us 149

Disclaimer 149


List Of Figure

List of Figures

Sanofi, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Sanofi, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Sanofi, Medical Equipment, Deals by Type, 2012 to YTD 2018 9

Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Sanofi, Medical Equipment, Deals by Market, 2012 to YTD 2018 11


List Of Table

List of Tables

Sanofi, Medical Equipment, Key Facts, 2017 2

Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Sanofi, Medical Equipment Deals By Type, 2012 to YTD 2018 9

Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Sanofi, Deals By Market, 2012 to YTD 2018 11

Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 12

Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 15

Sanofi Plans to Acquire Medical Device Assets 16

True North Therapeutics Raises USD45 Million in Series D Financing 17

Portal Instruments Raises USD25 Million in Series B Financing 18

Portal Instruments Raises USD11 Million in Series A Venture Financing 19

Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 20

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 22

Ablynx Exercises Option for Licensing Agreement with Vectura 23

Sensile Medical, Sanofi and Verily Enter into Co-Development Agreement 24

Adaptive Biotechnologies Enters into Agreement with Sanofi 25

Berg Enters into Research Agreement with Sanofi 26

Bioverativ and Invicro Enter into Agreement 27

Sanofi and Voluntis Enter into Agreement 28

R-Health Enters into Agreement with Bioverativ 29

Sanofi and Verily Life Sciences Form Joint Venture 30

Global Genomics Enters into Research Agreement with Sanofi 31

Google Life Sciences Enters into Agreement with Sanofi 32

Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33

Sanofi Enters into Co-Development Agreement with Medtronic 34

Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 35

HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 36

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 37

Sanofi Japan and Genzyme Japan Merge 38

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 39

Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 40

JHL Biotech Raises USD80 Million in Private Placement of Shares 41

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 42

Ablynx Raises USD57 Million in Private Placement of Shares 43

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 44

Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 45

Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 46

Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 47

Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 48

Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 49

Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 50

Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 51

Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 52

Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 53

Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 54

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 55

Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 56

Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 57

Sanofi Prices Public Offering Of Bonds Due 2023 For USD 1.35 Billion 58

Sanofi Prices Public Offering Of Bonds Due 2020 For USD 1.3 Billion 59

Sanofi Completes Public Offering Of Notes Due 2018 For USD 1.5 Billion 60

Sanofi Completes Public Offering Of Notes Due 2017 For USD 960 Million 62

Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 63

Bioverativ Therapeutics Acquires True North Therapeutics 65

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 66

Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For USD 123 Million 67

L'Oreal Plans To Sell Its Stake In Sanofi 68

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 69

Sanofi Completes Acquisition Of Pluromed 71

Sanofi, Key Competitors 72

Sanofi, Key Employees 73

Sanofi, Subsidiaries 75

Sanofi, Joint Venture 89

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Sanofi, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.